These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24166524)

  • 1. Is fidaxomicin the drug of choice for treating Clostridium difficile-associated diarrhea in patients with cancer?
    Green MR; Acharya UH; Yeager AM
    J Clin Oncol; 2013 Dec; 31(34):4376-8. PubMed ID: 24166524
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to M.R. Green et al.
    Cornely OA; Miller MA; Fantin BR; Mullane KM; Kean Y; Gorbach SL
    J Clin Oncol; 2013 Dec; 31(34):4379. PubMed ID: 24166523
    [No Abstract]   [Full Text] [Related]  

  • 3. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin.
    Cornely OA; Miller MA; Fantin B; Mullane K; Kean Y; Gorbach S
    J Clin Oncol; 2013 Jul; 31(19):2493-9. PubMed ID: 23715579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fidaxomicin approved for C. difficile infections.
    Traynor K
    Am J Health Syst Pharm; 2011 Jul; 68(14):1276. PubMed ID: 21719581
    [No Abstract]   [Full Text] [Related]  

  • 5. [Antimicrobial therapy of Clostridium difficile infection. Systematic review and meta-analysis of the scientific evidence].
    Brodszky V; Gulácsi L; Ludwig E; Prinz G; Banai J; Reményi P; Strbák B; Kertész A; Kopcsóné Németh I; Zsoldiné Urbán E; Baji P; Péntek M
    Orv Hetil; 2013 Jun; 154(23):890-9. PubMed ID: 23728312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
    Cornely OA; Crook DW; Esposito R; Poirier A; Somero MS; Weiss K; Sears P; Gorbach S;
    Lancet Infect Dis; 2012 Apr; 12(4):281-9. PubMed ID: 22321770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fidaxomicin "chaser" regimen following vancomycin for patients with multiple Clostridium difficile recurrences.
    Johnson S; Gerding DN
    Clin Infect Dis; 2013 Jan; 56(2):309-10. PubMed ID: 23024296
    [No Abstract]   [Full Text] [Related]  

  • 8. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
    N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress with a difficult infection.
    Wilcox MH
    Lancet Infect Dis; 2012 Apr; 12(4):256-7. PubMed ID: 22321771
    [No Abstract]   [Full Text] [Related]  

  • 10. Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea.
    Johnson S; Gerding DN; Louie TJ; Ruiz NM; Gorbach SL
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4043-5. PubMed ID: 22615287
    [No Abstract]   [Full Text] [Related]  

  • 11. Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin.
    Biswas JS; Patel A; Otter JA; Wade P; Newsholme W; van Kleef E; Goldenberg SD
    J Hosp Infect; 2015 Jul; 90(3):267-70. PubMed ID: 25728208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clostridium difficile infection in older adults: a review and update on its management.
    Kee VR
    Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic.
    Sears P; Ichikawa Y; Ruiz N; Gorbach S
    Ann N Y Acad Sci; 2013 Jul; 1291():33-41. PubMed ID: 23672600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.
    Cornely OA; Nathwani D; Ivanescu C; Odufowora-Sita O; Retsa P; Odeyemi IA
    J Antimicrob Chemother; 2014 Nov; 69(11):2892-900. PubMed ID: 25074856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections.
    Poxton IR
    Future Microbiol; 2010 Apr; 5(4):539-48. PubMed ID: 20353295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fidaxomicin--the new drug for Clostridium difficile infection.
    Vaishnavi C
    Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
    Lancaster JW; Matthews SJ
    Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea.
    Clutter DS; Dubrovskaya Y; Merl MY; Teperman L; Press R; Safdar A
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4501-5. PubMed ID: 23836168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.
    Nelson RL; Kelsey P; Leeman H; Meardon N; Patel H; Paul K; Rees R; Taylor B; Wood E; Malakun R
    Cochrane Database Syst Rev; 2011 Sep; (9):CD004610. PubMed ID: 21901692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of fidaxomicin for treatment of relapsed Clostridium difficile infections in patients with cancer.
    Esmaily-Fard A; Tverdek FP; Crowther DM; Ghantoji SS; Adachi JA; Chemaly RF
    Pharmacotherapy; 2014 Nov; 34(11):1220-5. PubMed ID: 25164587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.